Mark J Niciu

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institutes of Health National Institute of Mental Health, Bethesda, Maryland 20814 9692 email
    Annu Rev Pharmacol Toxicol 54:119-39. 2014
  2. doi request reprint Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder
    Mark J Niciu
    Yale University, Department of Psychiatry Connecticut Mental Health Center CMHC, Clinical Neuroscience Research Unit CNRU, New Haven, Connecticut, USA
    J Psychopharmacol 27:651-4. 2013
  3. ncbi request reprint Clinical predictors of ketamine response in treatment-resistant major depression
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program IRP, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, Maryland
    J Clin Psychiatry 75:e417-23. 2014
  4. pmc Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder
    Mark J Niciu
    1 National Institutes of Health National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, Bethesda, Maryland, USA
    CNS Spectr 18:242-51. 2013
  5. pmc Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland
    Depress Anxiety 31:297-307. 2014
  6. doi request reprint Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder
    Mark J Niciu
    1 National Institutes of Health NIH National Institute of Mental Health NIMH, Experimental Therapeutics and Pathophysiology Branch ETPB, Intramural Research Program, Bethesda, Maryland, USA
    CNS Spectr 18:231-41. 2013
  7. pmc Do the dissociative side effects of ketamine mediate its antidepressant effects?
    David A Luckenbaugh
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, MD USA
    J Affect Disord 159:56-61. 2014
  8. pmc Defining anxious depression: a review of the literature
    Dawn F Ionescu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    CNS Spectr 18:252-60. 2013
  9. pmc Neurobiology of anxious depression: a review
    Dawn F Ionescu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Depress Anxiety 30:374-85. 2013
  10. doi request reprint Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?
    Mark J Niciu
    Yale University Department of Psychiatry Connecticut Mental Health Center CMHC, Clinical Neuroscience Research Unit CNRU, New Haven, CT, USA
    World J Biol Psychiatry 15:2-16. 2014

Detail Information

Publications11

  1. pmc Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institutes of Health National Institute of Mental Health, Bethesda, Maryland 20814 9692 email
    Annu Rev Pharmacol Toxicol 54:119-39. 2014
    ....
  2. doi request reprint Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder
    Mark J Niciu
    Yale University, Department of Psychiatry Connecticut Mental Health Center CMHC, Clinical Neuroscience Research Unit CNRU, New Haven, Connecticut, USA
    J Psychopharmacol 27:651-4. 2013
    ..We conclude that there remains insufficient data on therapeutic ketamine in the presence of comorbid psychiatric disorders to promote its off-label use in a non-research milieu. ..
  3. ncbi request reprint Clinical predictors of ketamine response in treatment-resistant major depression
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program IRP, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, Maryland
    J Clin Psychiatry 75:e417-23. 2014
    ..Clinical predictors may identify those more likely to benefit from ketamine within clinically heterogeneous populations...
  4. pmc Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder
    Mark J Niciu
    1 National Institutes of Health National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, Bethesda, Maryland, USA
    CNS Spectr 18:242-51. 2013
    ..Even in the past decade, intracellular dysfunction in numerous neuroprotective/apoptotic cascades appears important in the pathophysiology and may be a future target for pharmacological interventions of BD. ..
  5. pmc Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants
    Mark J Niciu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland
    Depress Anxiety 31:297-307. 2014
    ..In sum, the combination of target engagement and well-qualified disease-related measures are crucial to improve our pathophysiological understanding, personalize treatment selection, and expand our armamentarium of novel therapeutics. ..
  6. doi request reprint Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder
    Mark J Niciu
    1 National Institutes of Health NIH National Institute of Mental Health NIMH, Experimental Therapeutics and Pathophysiology Branch ETPB, Intramural Research Program, Bethesda, Maryland, USA
    CNS Spectr 18:231-41. 2013
    ..Throughout this discourse, we will highlight potential intracellular targets for therapeutic intervention. Finally, future clinical implications are discussed. ..
  7. pmc Do the dissociative side effects of ketamine mediate its antidepressant effects?
    David A Luckenbaugh
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, MD USA
    J Affect Disord 159:56-61. 2014
    ..Psychotomimetic symptoms, dissociation and hemodynamic changes are known side effects of ketamine, but it is unclear if these side effects relate to its antidepressant efficacy...
  8. pmc Defining anxious depression: a review of the literature
    Dawn F Ionescu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    CNS Spectr 18:252-60. 2013
    ....
  9. pmc Neurobiology of anxious depression: a review
    Dawn F Ionescu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Depress Anxiety 30:374-85. 2013
    ..Because exploring the neurobiology of this depressive subtype is important for improving diagnosis, prognosis, and treatment, enrichment strategies to decrease heterogeneity within the field should be employed for future research...
  10. doi request reprint Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?
    Mark J Niciu
    Yale University Department of Psychiatry Connecticut Mental Health Center CMHC, Clinical Neuroscience Research Unit CNRU, New Haven, CT, USA
    World J Biol Psychiatry 15:2-16. 2014
    ....
  11. pmc NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia
    Alan Anticevic
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 109:16720-5. 2012
    ..Together, the present findings establish links between glutamate's role in the organization of large-scale anticorrelated neural systems, cognition, and symptoms associated with schizophrenia in humans...